Creative Bioarray DDA Platform Releases kinase Assay Services in Order to Satisfy The Needs of Drug Discovery Research

DDA Platform, as the division of Creative Bioarray, announces the release of its brand new kinase assay service in order to satisfy the needs of drug discovery research.

New York, USA - November 28, 2019 /MarketersMedia/

DDA Platform, as the division of Creative Bioarray, focuses on developing unique biotechnology technologies with high quality products and services to facilitate the investigation of research in various fields. Recently this platform announces the release of its brand new kinase assay service in order to satisfy the needs of drug discovery research.

Protein kinases represent one of the most promising drug targets because they are involved in pathological conditions such as cancer, inflammatory diseases, neurological diseases and metabolic problems. Protein kinases play an integral role in many cellular signaling pathways and are one of the largest families of homologous proteins in the human proteome. Thus, protein kinases represent the largest "absorbable" gene family in the human genome. Overexpression and/or dysregulation of protein kinases can cause many diseases, providing many targets for drug development. In view of the huge demand for small molecules that target such proteins, Creative Bioarray has developed techniques and platforms for the discovery of kinase inhibitors, including biochemical-based functional assays and compound binding competition assays.

Radiometric-based Assays, known as the most reliable method for detecting kinase responses, are the preferred method for kinase profiling. In Creative Bioarray, we can support two major methods, including Filtration binding assay and Scintillation proximity assay. Filtration binding assays can be used without restriction for any kinase and substrate. This method does not require any special substrate labeling or modification and is not interfered with by compounds and unreacted radioisotopes.

Kinase assay formats using Fluorescence-based Detection assays are the most widely used methods for HTS-based kinase drug discovery because they are easy to automate, easy to use, relatively inexpensive, and widely available. In this type of analytical method, some of the more commonly used techniques use FP, FRET and TRF to identify lead compounds, in which, FI is arguably the most common method for detecting enzymatic activity based on fluorescence, and is widely used in detection methods using protease-based detection reactions. FP is a technique for monitoring molecular motion and rotation and is a widely used detection method for kinase inhibitors in HTS. The principle of this assay is that molecules with high molecular weight will have a slower rotational motion than molecules with low molecular weight when excited by polarized light.

“Creative Bioarray has decades of experience in providing kinase products and services to meet a variety of drug discovery research needs. Whether you need high-quality, active proteins for internal research and drug discovery screening, or want to outsource custom protein production, assay development and kinase selectivity analysis, our team can support your project.” said Hannah Cole, the marketing director of Creative Bioarray, she also said, “We can customize the exclusive solution according to your needs, our experts and platform can guarantee the delivery of the final result.”

About DDA platform
As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.

Contact Info:
Name: Hannah Cole
Email: Send Email
Organization: Creative Bioarray
Address: 45-1 Ramsey Road, Shirley, NY 11967, USA
Phone: 06316197922

Source URL:

Source: MarketersMedia

Release ID: 88936424

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.